Clinical Trial Update: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating personalized reduction of chemotherapy intensity in advanced Hodgkin lymphoma guided by ctDNA measurements.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Snippet

Sponsor: University of Washington | Conditions: Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Status: RECRUITING